Skip to content Skip to navigation

NIDA: Mirtazapine shows promise in reducing methamphetamine use

November 9, 2011
by News release
| Reprints

Methamphetamine is a highly addictive stimulant drug for which no FDA-approved medication currently exists. A preliminary (small sample) NIDA-funded clinical trial shows that mirtazapine, an FDA-approved medication for the treatment of depression, reduces methamphetamine use as well as associated sexual risk behaviors in men who have sex with men.

Given the devastating consequences of methamphetamine abuse, including its link to an increased risk of HIV infection, further research is warranted to determine whether this medication could help in the battle against methamphetamine addiction and its consequences.

For a copy of the article, click here. To watch a video interview of the first author, in which he discusses amphetamine use and risky behaviors related to an increased risk for HIV infection, click here.

For more information, please contact the NIDA Press Office at (301) 443-6245 or media@nida.nih.gov.

Topics